



## **Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019**

February 21, 2019 at 6:30 AM EST

LONDON, Feb. 21, 2019 /PRNewswire/ -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that the company will release its operating and financial results for the transition period from October 1, 2018 to December 31, 2018 before the opening of U.S. markets on Monday, February 25, 2019. The transition period is necessary to accommodate the change in the company's financial year end from September 30 to December 31.

Management will host a conference call at 8:00 a.m. ET/ 1:00pm GMT the same day to discuss the company's financial results and provide an operational update. To listen to the webcast and view the accompanying slide presentation, please go to: <https://www.autolus.com/investor-relations/news-events/events>.

The call may also be accessed by dialing 877-270-2148 (U.S.) or 412-902-6510 (international) and asking the operator to join the Autolus Therapeutics conference call. After the conference call, a replay will be available for one week. To access the replay, please dial 877-344-7529 (U.S.) or 412-317-0088 (international) and enter replay access code 10129000.

### **About Autolus Therapeutics plc**

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit [www.autolus.com](http://www.autolus.com).

#### **Investor contact:**

Susan A. Noonan  
S.A. Noonan Communications  
+1-212-966-3650  
[susan@sanoonan.com](mailto:susan@sanoonan.com)

#### **Media contact:**

Silvia Taylor  
Vice President, Corporate Affairs  
and Communications, Autolus  
+1-240-801-3850  
[s.taylor@autolus.com](mailto:s.taylor@autolus.com)

#### **Media contact (UK):**

Julia Wilson  
JW Communications  
+44 (0) 7818 430877  
[juliawilsonuk@gmail.com](mailto:juliawilsonuk@gmail.com)

 View original content: <http://www.prnewswire.com/news-releases/autolus-therapeutics-to-announce-financial-results-for-the-transition-period-from-october-1-2018-to-december-31-2018-and-host-conference-call-on-february-25-2019-300799385.html>

SOURCE Autolus Therapeutics plc